Posts Tagged ‘nasdaq’

Netflix, Inc. (NFLX) – Buzz Stock of the Day

Thursday, October 21st, 2010

Shares of Netflix, Inc. (Nasdaq: NFLX) were up more than 14 percent from Wednesday’s closing price, in morning trading on Thursday after the movie rental company announced third quarter earnings that edged out the Street’s estimates, largely driven by a higher number of customers that rent movies online, and lower subscription acquisition costs.

Netflix posted revenue of $553.2 million, up from $423.1 million a year ago. Excluding stock-based compensation, Netflix earned 78 cents per share, although GAAP earnings were 70 cents per share, just shy of analysts’ estimates of 71 cents.  Netflix ended the quarter with 16.9 million subscribers, up 13 percent sequentially and 52 percent over the third quarter of last year.  Gross margin dipped to 37.7 percent from 39.4 percent in Q2.
[–quote–]
The company said 66 percent of its subscribers watched streaming videos in the quarter, up from 41 percent a year ago. Subscriber acquisition costs fell to $19.81 in the quarter, from $26.86 a year ago. Churn fell to 3.81 percent, from 4.4 percent a year ago.

Netflix now sees ending Q4 with 19 million to 19.7 million subscribers, up from a previous estimate of 17.7 million to 18.5 million. The company now sees Q4 revenue earnings of between 59 cents and 74 cents per share, and revenue between $586 million and $598 million, up from earlier estimates $580 million to $596 million.

“Q3 represents our fourth consecutive quarter of more than one million net subscriber additions,” said Reed Hastings, co-founder and CEO of Netflix in a statement. “This growth is clearly driven by the strength of our streaming offering.  In fact, by every measure, we are now primarily a streaming company that also offers DVD-by-mail,” said Reed Hastings, Netflix co-founder and CEO.  “At the same time, the introduction of our streaming offering in Canadain late September has provided us with very encouraging signs regarding the potential for the Netflix service internationally.”

Several analysts upgraded their ratings of Netflix, including Oppenheimer analyst Jason Helfstein, who raised his rating on Netflix shares to Outperform from Underperfrom; Janney Capital analyst Tony Wible, who raised his rating to Neutral from Sell; Merriman Capital analyst Eric Wold, who raised his rating on Netflix shares to Buy from Neutral; and Needham analyst Charlie Wolf, who trimmed his 2010 EPS estimate to $2.85 from $2.90, but lifted his 2011 view to $4.55 from $4.00.

“Our original thesis was dependent on Hollywood reacting to the NFLX competitive threat through various ways, including its own IPTV service (Hulu), new services with cable companies (TV Everywhere) and reducing the amount of TV content available to NFLX,” Helfstein wrote. “None of this has happened, and we are now at the beginning of the IPTV revolution, with NFLX in the dominant position.”

PharmAthene, Inc. (PIP) – Buzz Stock of the Day

Monday, October 18th, 2010

Shares of biodefense company PharmAthene, Inc. (AMEX: PIP) soared almost 32 percent from Friday’s closing price, in morning trading on Monday after WBB Securities upgraded its rating on the stock to a Strong Buy. The tailwind for PharmAthene began last week after it was announced that the  NYSE Amex LLC (NYSE Amex) determined that the Company made a reasonable demonstration of its ability to regain compliance with the  NYSE Amex listing requirements and granted PharmAthene an extension until January 26, 2012 to demonstrate its compliance.

PharmAthene also caught a huge boost from last week’s news that the United States is spending up to $2.8 billion to shore up its defenses against biological warfare, according to SIGA Technologies, Inc. (Nasdaq: SIGA), the drugmaker who expects to get a government contract to supply smallpox antiviral drugs.In December 2006, PharmAthene had filed a case against SIGA pursuant to a merger agreement between the companies that was terminated in October 2006. The trial is expected to start on Jan. 3, 2011. Noble Financial Capital Markets analyst Raghuram Selvaraju expects the court case with PharmAthene to be ruled in its favor, with PharmAthene getting a percentage of SIGA’s contract with the government. Roth Capital Partners analyst Joseph Pantginis said the contract has positive implications to PharmAthene that can now identify the exact measure of potential damages.
[–quote–]
TheStreet.com’s James Altucher recently wrote that on the basis of this contract alone, Pharmathene would potentially make up to a billion dollars in cash earnings. “On this one catalyst I think PIP is potentially a $7 – $12 stock,” he stated in his October 15, 2010 article.

PharmAthene is also positioning its anthrax vaccine, Valortim, as a potential alternative to the existing vaccine that is administered to military personnel and individuals who work in high-risk environments. Anthrax is considered the Department of Defense’s No. 1 biological threat.  The US is required to have a stockpile of 75 million doses of vaccine. Right now, the only approved supplier of doses of vaccine is EBS, which has a long-approved first-generation vaccine that requires 5 doses over 18 months and costs $120 per dose. PIP’s second-generation vaccine requires 3 doses over 60 days and costs about $45 a dose, according to PharmAthene’s Chief Executive Officer, Eric Richman.

ZAGG, Inc. (ZAGG) – Buzz Stock of the Day

Thursday, October 14th, 2010

Shares of mobile device accessory maker, ZAGG, Inc. (Nasdaq: ZAGG) soared as much as 44 percent from Wednesday’s closing price, in morning trading on Thursday after the company announced that it expects higher third quarter and full-year revenue than previously stated.

The Salt Lake City-based company announced that it now expects third quarter 2010 revenues to exceed $22 million, and now guides for full year 2010 revenue growth of 70 percent. This compares to previously issued revenue guidance of 30 percent growth over 2009 results. The main reasons behind the revised guidance were stronger demand for their flagship product, the invisibleSHIELD, more SKUs shipped to existing storefronts, and the successful introduction of various new mobile devices in the quarter.
[–quote–]
Analysts on average expect revenue of $14.6 million, according to Thomson Reuters I/B/E/S.

“Preliminary results for the quarter have exceeded our expectations due to the timing of distribution agreements and new mobile devices sales surpassing industry expectations,” said ZAGG’s President and CEO, Robert G. Pedersen II, in a statement. “Demand has continued to exceed our distributors’ forecasts for the invisibleSHIELD, and we have been successful in getting more branded ZAGG products into the retail distribution channel. The rapid acceptance of mobile devices in the third quarter has also been an important driver for ZAGG sales, and we see this trend continuing in the future.”

ZAGG expects to report financial and operating results for the third quarter ended September 30, 2010, on November 10.

Motricity, Inc. (MOTR) – Buzz Stock of the Day

Wednesday, October 13th, 2010

Shares of mobile data services provider, Motricity, Inc. (Nasdaq: MOTR) soared as much as 22 percent from Tuesday’s closing price, in morning trading on Wednesday. This marks the second day Motricity shares rose,  after the company announced through a regulatory filing, that it signed an agreement to roll out its mCore service with Indian wireless carrier Reliance Communications Ltd.

Motricity was up as much as 40 percent from Monday’s closing price, on Tuesday.
[–quote–]
Motricity said the service, which lets wireless carriers get their users onto the Internet via mobile devices such as cell phones, will be used for Reliance’s mobile data services business.

At the time Motricity filed its IPO in January, the company had already generated more than $100 million in revenue in 2008. And although it was not yet profitable, was expecting to raise as much as $250 million from investors in its IPO. Ultimately, Motricity ended up settling on a much lower $50 million to close the deal.

Motricity trimmed its 2009 net loss to $16 million, down from $78 million in 2008. Revenue for 2009 clocked in at $113 million.

Although the company did not disclose financial terms of the Reliance deal, Baird analyst William V. Power called the deal “significant.”

“While the overall revenue opportunity is lower in India vs. developed markets, we expect that to change as data penetration improves,” he wrote in a note to investors.

Using Vodafone India as a proxy, Power estimated that the deal could add $15.2 million to $30.8 million to Motricity’s annual revenue.

Neurocrine Biosciences, Inc. (NBIX) – Buzz Stock of the Day

Friday, October 8th, 2010

Shares of neurological and endocrine-related drug maker, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) soared as much as 16 percent from Thursday’s closing price, in morning trading on Friday on news that Jefferies & Co. had initiated coverage of the stock with a buy rating. Neurocrine shares touched a high of $7.37 per share in morning trading, up from Thursday’s closing price of $6.34.

We covered Neurocrine Biosciences in early June 2010 after the company announced a development deal with privately held German drug maker, Boehringer Ingelheim. Prior to that, Neurocrine was a Buzz Stock of the Day in May2010 after the company announced “statistically significant and clinically meaningful” top-line efficacy results from its Daisy PETAL phase II study of elagolix, a treatment for patients with endometriosis.

[–quote–]

In mid-September, Neurocrine said that a potential treatment for major depressive disorder conferred no benefit on patients in a midstage study. The study on GSK561679 involved 150 patients and was conducted by partner GlaxoSmithKline. It compared the drug candidate with placebo. Neurocrine said it plans to meet with GlaxoSmithKline in the coming months after full clinical data are available to discuss next steps for the program. Other ongoing clinical trials on the drug are testing it against post-traumatic stress disorder, anxiety and alcoholism.

Despite the setback, shares of Neurocrine are trading near their 52-week high.